Concord Biotech approves 1:1 bonus issue and raises capital to ₹22 crore
- Concord Biotech approved a 1:1 bonus issue for shareholders
- Authorised share capital increased from ₹11 crore to ₹22 crore
- Bonus shares to be credited by November 22, 2026
- Proposal remains subject to shareholder approval
*this image is generated using AI for illustrative purposes only.
Concord Biotech Limited approved a 1:1 bonus issue and an increase in authorised share capital to ₹22 crore during its board meeting held on September 23, 2026. The proposal remains subject to shareholder approval.
The trading window for designated persons and their immediate relatives remained closed from September 19, 2026, until 48 hours after the outcome of the meeting. Trading resumed on September 26, 2026.
Bonus Issue Details
The Board approved the issuance of bonus equity shares in the proportion of 1:1, meaning one fully paid-up equity share of ₹1 each for every one existing equity share held by shareholders as on the record date. This issuance will be executed by capitalising the share premium account.
| Particulars | Details |
|---|---|
| Type of securities | Equity shares of ₹1 each |
| Bonus ratio | 1:1 |
| Total number of shares | 10,46,16,204 |
| Source of funds | Share premium account |
| Pre-bonus paid-up capital | ₹10,46,16,204 |
| Post-bonus paid-up capital | ₹20,92,32,408 |
| Estimated credit date | By November 22, 2026 |
Authorised Capital Increase
Concurrently, the Board approved an increase in the Company’s authorised share capital from ₹11 crore to ₹22 crore. This involves the creation of an additional 11,00,00,000 equity shares of ₹1 each, ranking pari passu with existing shares. Consequently, Clause V of the Memorandum of Association will be amended to reflect the new authorised capital structure.
Regulatory Compliance
The intimation was issued pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company notified both the National Stock Exchange of India Limited and BSE Limited regarding the scheduled meeting and its outcomes.
Paritosh Trivedi, Company Secretary & Compliance Officer, signed the disclosure on September 23, 2026.
Historical Stock Returns for Concord Biotech
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +1.82% | +5.93% | -0.70% | +42.85% | -3.72% | +65.50% |
How will the 1:1 bonus issue impact Concord Biotech's future dividend per share and overall payout ratio?
What specific expansion projects or R&D initiatives is the company planning to fund using the newly increased authorised share capital?
Will the doubling of share count affect the stock's liquidity profile and potential inclusion in broader market indices?
20
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
